2Davies AM, Ho C, Metzger AS, et al. Phase Ⅰ study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol, 2007, 2(12) :1112-1116.
3Ramirez PT, Landen CN Jr, Coleman RL, et al. Phase Ⅰ trial of the proteaxsome inhibitor bortezomib in combination with carboplatin in patients with platinum-and taxane-resistant ovarian cancer. Gynecol Oncol, 2008,108( 1 ) :68-71.
4Brun J. Proteasome inhibition as a novel therapy in treating rheumatoid arthritis. Med Hypotheses,2008,71 ( 1 ) :65-72.
5Voorhees PM, Dees EC, O' Neil B, et al. The proteasome as a target for cancer therapy. Clin Cancer Res,2003,9 (17) : 6316-6325.
7Aghajanian C, Soigent S, Dizon DS,et al. A phase Ⅰ trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res, 2002, 8 (8) : 2505- 2511.
8Meister S, Schubert U, Neubert K,et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res ,2007,67 (4) : 1783-1792.
9Pelletier N, Casamayor-Palleja M , De Luea K, et al. The endoplasmic reticulum is a key component of the plasma cell death pathway. J Immunol,2006,1 76 ( 3 ) : 1340-1347.
10Davies FE, Wu P, Jenner M, et al. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica, 2007,92 ( 8 ) : 1149-1150.
